Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
about
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerGrowth factor and signaling pathways and their relevance to prostate cancer therapeuticsThe role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsisBone-targeting agents in prostate cancer.The best of both worlds - managing the cancer, saving the bone.A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).Perspectives on treatment of metastatic castration-resistant prostate cancer.Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapyNovel bone-targeting agents in prostate cancer.Nonmetastatic castration-resistant prostate cancer.Prostate cancer: preventing metastasis to bone: is this the end of the story?Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.The role of the endothelin axis in promoting epithelial to mesenchymal transition and lymph node metastasis in prostate adenocarcinoma.Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
P2860
Q26796568-69F1C2E4-2D83-43B9-A0CE-6777ECC51B86Q26827975-FE440095-3437-4B86-874A-3770F0CC0408Q27009064-0F0FFFA4-FB7D-44D8-A80C-3C3AC743B036Q33864723-6F649F2C-448F-4B00-B4B6-2E9057E8ED75Q33920055-1E48D7D2-41F1-4F3B-9399-D24B71ACCBB7Q35698539-80C676A1-18DF-4893-8E41-9409C7A8B1C3Q35879087-D5341F19-603B-4325-B18A-05866A078C11Q36260345-49AD3108-2FBD-4429-A4E0-670BE3D777CFQ36871685-545CFB31-D427-42FA-9B9C-36B26C82A13DQ38116358-2EC20153-98FD-490B-BBB2-217C3E5E42C2Q38177688-7C7B4B39-6F98-4B61-B342-D051BF44E9A3Q38198934-23B0B21F-165E-478A-B26E-9105BBD1B631Q38306052-82071058-42CE-4B40-A436-A985881A46F2Q39209902-1520E331-D1A0-4C97-B7C8-7DD3A1ECD658Q40846608-48356082-EC09-4F5B-B01B-C7D1B5A55F92Q45454130-5D088684-47EA-4BD6-A27A-4E7D047BBB8AQ52649233-38067A43-97EF-4C49-ABFD-FFBD3A13EC1C
P2860
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Phase III, randomized, placebo ...... ion-resistant prostate cancer.
@en
Phase III, randomized, placebo ...... ion-resistant prostate cancer.
@nl
type
label
Phase III, randomized, placebo ...... ion-resistant prostate cancer.
@en
Phase III, randomized, placebo ...... ion-resistant prostate cancer.
@nl
prefLabel
Phase III, randomized, placebo ...... ion-resistant prostate cancer.
@en
Phase III, randomized, placebo ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P356
P1476
Phase III, randomized, placebo ...... ion-resistant prostate cancer.
@en
P2093
C S Higano
F E Nathan
J B Nelson
K Pemberton
S McIntosh
P2860
P2888
P304
P356
10.1038/PCAN.2013.2
P577
2013-02-05T00:00:00Z
P5875
P6179
1022620264